MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, ...
Joplin Globe1mon
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. In December 2023, the Company ...
Nasdaq1mon
MedMira Expands Market with Strategic Approvals
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter MedMira Inc. has reported progress in expanding its market presence and securing regulatory approvals.
GlobalData on MSN2d
Health Canada approves MedMira’s rapid test for HIV and syphilis
The test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.
Morningstar1mon
MedMira Reports FY2024 Fourth Quarter and Year End Financial Results
The Company's completed clinical trials showed a sensitivity of 100% for HIV-1 and HIV-2 MedMira's Reveal® G4 HIV-1/2 rapid antibody test achieved a flawless 100% specificity and was reactive in ...
Morningstar4d
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo ...
Pharmabiz2d
Health Canada approves MedMira’s Multiplo Rapid TP/HIV test for Syphilis and HIV
Health Canada approves MedMira’s Multiplo Rapid TP/HIV test for Syphilis and HIV: Halifax, Canada Friday, December 27, 2024, 10:00 Hrs [IST] MedMira Inc. (MedMira), a leading de ...